A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
第1相
完了
NCT06520553
| 対象疾患 | Healthy |
|---|
| 相 | 第1相 |
|---|
| スポンサー | Boehringer Ingelheim |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 8 名 |
|---|
| 介入（薬剤） | BI 1569912 (C-14), BI 1569912 (C-13) |
|---|
| 開始日 | 2024年8月26日 |
|---|
| 完了日 | 2024年10月3日 |
|---|
| 結果公開日 | 2026年5月22日 |
|---|
概要
The main objectives of this trial are: * To investigate basic pharmacokinetics of BI 1569912 and total radioactivity, including mass balance, excretion pathways and metabolism following oral administration of BI 1569912 (C-14) to healthy male subjects (test treatment, T). * To investigate the absolute bioavailability of BI 1569912 as single oral solution dose, using a single, concomitant intravenous micro-tracer administration of BI 1569912 (C-13) (reference treatment, R)
Fraction Excreted in Urine as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point (fe Urine,0-tz) of [14C]-Radioactivity
Up to 14 days. · Percentage of administered dose
| 10 Milligram (mg) BI 1569912 (C-14) Oral Solution (Test Treatment) | 57.0 ± 10.9 Percentage of administered dose |
|---|
Fraction Excreted in Faeces as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point (fe Faeces,0-tz) of [14C]-Radioactivity
Up to 14 days. · Percentage of administered dose
| 10 Milligram (mg) BI 1569912 (C-14) Oral Solution (Test Treatment) | 31.1 ± 62.9 Percentage of administered dose |
|---|
Total Recovery of [14C]-Radioactivity
Up to 14 days. · Percentage of administered dose
| 10 Milligram (mg) BI 1569912 (C-14) Oral Solution (Test Treatment) | 91.2 ± 12.7 Percentage of administered dose |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。